49LOW

PCK

PAINCHEK FPO [PCK]
PainChek Limited develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. The company offers PainChek, a clinically validated and regulatory cleared pain assessment technology that uses cameras in smartphones for a facial scan that is analyzed using facial recognition software to indicate the presence of pain. It serves patients suffering with dementia and pre-verbal infants; and the aged care, disability, home care, hospital, and infant sectors. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Healthcare · ASX Small Cap
$0.1500 +7.1%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical71
Catalyst52
Sentiment50
Fundamental56
Momentum30
Risk Gate42
Get alerts when PCK's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track PCK — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD just crossed bullish — momentum is shifting to the upside
  • Stochastic just turned bullish from a low level — early reversal sign
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Low cash runway (3 quarters) - dilution risk
  • Moderate P/S ratio (9.4x)
  • Near 52-week low (5% of range)
  • Small-cap ($20-100M)
  • Revenue growth 34580% YoY (from results)
  • Sentiment is mixed — no strong consensus either way
  • Poor risk-adjusted returns — Sharpe of -2.1 means lots of volatility for not much reward
  • Altman Z-Score distress zone (1.36 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Deeply negative margins (-268%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 46% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.66%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about PCK
"What's driving PCK's score?" "How does PCK compare to peers?" "Key risks for PCK?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE PainChek reports material sales momentum in UK
NONE Notification of cessation of securities - PCK
NONE Half Yearly Report and Accounts
LOW PainChek to present at NWR Virtual Healthcare Conference

Recent ASX Announcements

2026-03-25 PainChek reports material sales momentum in UK PRICE SENSITIVE
2026-03-23 PainChek to present at NWR Virtual Healthcare Conference
2026-03-03 Notification of cessation of securities - PCK
2026-02-27 Half Yearly Report and Accounts PRICE SENSITIVE
2026-02-11 Update - Notification regarding unquoted securities - PCK

Key Metrics

$32.4M
Market Cap
104K
Avg Volume
1.2x
Vol Ratio
$0.14 — $0.35
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-383.2%
ROE
-268.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 72%
LLeader vs LaggardlaggardRS: -11
IInstitutional SponsorshipweakInst: 2%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #45 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:PCK vs ATXPCK vs PNVPCK vs IMM
Scout Pro — Deeper Analysis for PCK
Try Pro free for 30 days
Share this analysis

Track PCK and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required